Vaccine revenues by Chinese vaccine maker Sinovac have surged beginning in the first half of 2021 amid China’s ban of foreign COVID-19 vaccines in the country. Sinovac Biotech Ltd. reported sales of $11 billion for the first half of 2021, up 162-fold from $67.7 million the previous year, with a net income of $8.6 billion, compared to a net loss of $8.7 million the previous year. Sinovac is headquartered in Beijing and listed on the NASDAQ. Its COVID vaccine is one of the vaccines approved by Chinese authorities for use in mainland China. China has banned the sale of all foreign vaccines in China, including Pfizer’s and Modena’s, which are widely used in Europe and the United States, and China’s homegrown vaccines dominate their domestic market. According to news reports in April 2021, Chinese officials were reviewing clinical trial data for a COVID-19 vaccine produced by Germany’s BioNTech SE (BNTX). …